Table 3.
Adverse events.
| Age/sex | Event | PGB dose at onset (mg/day) |
Onset (days after PGB prescription) |
Severity∗ | Causal association | PGB prescription | Special treatment |
|---|---|---|---|---|---|---|---|
| 76/M | Rash | 25 mg × 1 (25) |
5 | Mild | Unclear | Withdrawn | No |
| 76/F | Dizziness | 25 mg × 2 (50) |
14 | Mild | Yes | Withdrawn | No |
| 79/M | Nausea | 50 mg × 2 (100) |
30 | Mod. | Yes | Withdrawn | No |
| 79/M | Ataxia | 50 mg × 2 (100) |
30 | Mod. | Yes | Withdrawn | No |
| 79/M | Somnolentia | 25 mg × 2 (50) |
10 | Mild | No | Dose decreased | No |
| 81/M | Increased numbness | 75 mg × 2 (150) |
25 | Mod. | Unclear | Withdrawn | No |
| 82/M | Increased numbness | 25 mg × 1 (25) |
14 | Mod. | Unclear | Withdrawn | No |
| 78/F | Fever | 75 mg × 2 (150) |
33 | Mod. | Unclear | Withdrawn | No (blood test) |
| 78/F | Nausea | 75 mg × 2 (150) |
33 | Mod. | Unclear | Withdrawn | No |
| 64/F | Ataxia | 50 mg × 2 (100) |
14 | Mod. | Yes | Dose decreased | No |
| 64/F | Dizziness | 50 mg × 2 (100) |
14 | Mod. | Yes | Dose decreased | No |
| 64/F | Nausea | 50 mg × 2 (100) |
14 | Mod. | Yes | Dose decreased | No |
| 64/M | Rash | 25 mg × 1 (25) |
6 | Mod. | Unclear | Withdrawn | No |
| 71/F | Somnolentia | 25 mg × 2 (50) |
16 | Mild | Yes | Continued | No |
| 71/F | Ataxia | 25 mg × 2 (50) |
16 | Mild | Yes | Continued | No |
| 54/F | Weight gain | — | 231 | — | Unclear | Withdrawn | — |
| 73/F | Edema | — | 140 | Mild | Yes | Dose decreased | No |
| 74/M | Edema | 150 mg × 2 (300) |
35 | Mild | Yes | Dose decreased | No |
∗Mod.: moderate.